A mosquito-borne tropical disease
Dengue virus is spread by the Aedes aegypti mosquito. It is caused by a flavivirus and is a rapidly growing health problem in tropical and sub-tropical countries of the World. There are four antigenically distinct dengue virus serotypes (DENV-1 to -4). Following infection, some individuals may have asymptomatic disease, others might develop dengue fever, that can progress to the more severely debilitating hemorrhagic fever, vascular leakage, or the highly dangerous dengue shock syndrome, causing internal hemorrhage and organ dysfunction leading to death.
The annual cost of dengue is substantial. A 2015 estimate was in excess of US$ 9 Billion. This figure was driven Driving by direct costs attributed to patient care and indirect costs associated with lost productivity, lost wages etc. The vast majority of individuals touched by dengue are in low/middle income countries where often healthcare is provided on a self-pay basis where sickness benefits are limited to absent
Dengue infection has a substantial impact on the individuals well-being and ability to work contributing to the cost burden of the disease. Estimates of the duration of symptomatic disease are from 14-19 days.
Rapid Virus Neutralisation in Dengue in Serotype-1 Infected Human Blood
Blood infected with dengue serotype-1 virus is treated with GEN-Y’s serotype-1 mAb at various dose levels. The impact on viremia is measured 6 hours later.
The viral load is substantially reduced. This is statistically significant at 1μg and 3μg doses.
These findings demonstrate the potential speed and efficacy of the treatment.